KR102536812B1 - Composition for anti-allergy comprising extract of forsythia velutina - Google Patents

Abstract

Disclosed herein is an anti-allergic composition comprising an extract of longevity flower as an active ingredient. The composition provides an excellent anti-allergic effect even when using the longevity manliflower extract at a low concentration, and is harmless to the human body and has high safety due to no cytotoxicity. In addition, the composition is effective for preventing, improving and/or treating allergic rhinitis.

Description

Composition for anti-allergy containing Jangsu Manlihwa extract

The present disclosure discloses an anti-allergic composition comprising an extract of Jangsu Manlihwa as an active ingredient.

Allergic rhinitis (allergic rhinitis) shows symptoms such as sneezing, clear runny nose, nasal congestion, and at the same time heavy head and tears. It often appears at the turn of the year or during the cold season, and is often confused with a cold, which is different from a cold and is often accompanied by asthma or hives.

Allergic rhinitis is one of the autoimmune diseases accompanied by an inflammatory response, and in patients suffering from allergic rhinitis, interleukin-4 (IL-4), interleukin-5 (IL-5), and interleukin-13 (IL-13) 13) is known to increase.

Currently, anti-allergic agents, anti-histamines, antibiotics or anti-inflammatory drugs are prescribed for those suffering from allergic rhinitis. Histamine secreted by the cellular immune response causes inflammation of blood vessels. Under normal circumstances, histamine secretion helps prevent infection, but when it reacts to an antigen such as pollen, it causes allergy. At this time, antihistamines act by suppressing histamine secreted from cells to prevent infection. In general, antihistamines do not have a high therapeutic effect on allergic rhinitis, and cause drowsiness, dizziness, dry mouth, excitement, and loss of appetite. There may be side effects such as , abdominal pain and constipation. It is also known to have no effect on nasal congestion. In addition, since antihistamines are not a fundamental treatment but temporarily control symptoms, their efficacy is 12-24 hours. Therefore, there is a problem in that antihistamines must be taken continuously, but it is not desirable to take them every day because they are metabolized by the liver or kidneys and absorbed throughout the body when taking antihistamines.

In addition, as one of the prescriptions for allergic rhinitis, topical steroids sprayed in the nose are used to relieve nasal congestion. This also relieves symptoms at the moment of use, but it can cause sinusitis if used for a long time, so it is used for more than 2 weeks. You shouldn't. Antibiotics and anti-inflammatory drugs also only serve to relieve symptoms temporarily. In this way, since a method capable of curing allergic rhinitis is not yet known, there is a high demand for a therapeutic agent for allergic rhinitis with excellent therapeutic effect without side effects.

KR 10-2011-0077131 A

In one aspect, an object of the present disclosure is to provide an anti-allergic composition comprising an extract of Jangsu Manlihwa as an active ingredient.

In one aspect, the present disclosure provides an anti-allergic composition comprising Forsythia velutina Nakai extract as an active ingredient.

In an exemplary embodiment, the extract may be extracted with one or more solvents selected from the group consisting of water and lower alcohols having 1 to 4 carbon atoms.

In an exemplary embodiment, the extract may be an aqueous ethanol extract.

In one exemplary embodiment, the extract may be included in a concentration of 1 to 1,000 ppm (w / v).

In an exemplary embodiment, the composition may inhibit phosphorylation of STAT6.

In an exemplary embodiment, the composition may be a pharmaceutical composition for preventing or treating allergic rhinitis.

In one exemplary embodiment, it may be a food composition for improving allergic rhinitis (allergic rhinitis).

In one aspect, the technology disclosed in the present disclosure has the effect of providing an anti-allergic composition comprising the longevity manliflower extract as an active ingredient. The composition provides an excellent anti-allergic effect even when the extract of Jangsu Manlihwa is used at a low concentration, and is harmless to the human body and has high safety because there is no cytotoxicity. In addition, the composition is effective for preventing, improving and/or treating allergic rhinitis.

Figure 1 is a result of evaluating the cytotoxicity of the longevity manlihwa extract according to one experimental example.
Figure 2 compares the cytotoxicity evaluation results of forsythia extract, Yeongyo extract and Jangsu manlihwa extract according to an experimental example.
Figure 3 is a result of evaluating the STAT6 activity inhibitory efficacy of the longevity manlihwa extract according to an experimental example.
Figure 4 compares the results of the evaluation of the STAT6 activity inhibitory efficacy of the forsythia extract, the Yeongyo extract, and the Jangsu Manlihwa extract according to an experimental example.
Figure 5 is a result of evaluating the degranulation inhibitory efficacy of the longevity manlihwa extract according to one experimental example.
Figure 6 is a rhinitis inhibitory efficacy evaluation results of the longevity manlihwa extract according to one experimental example (*p <0.05, **p <0.1).
Figure 7 is a rhinitis inhibitory efficacy evaluation results of the longevity manlihwa extract according to one experimental example (*p <0.05, **p <0.01, Scale bar = 50 μm). Dotted arrows and yellow arrows indicate nasal mucosal thickness and eosinophils, respectively, and data represent mean±SEM.
8 is a result of evaluating the rhinitis inhibitory efficacy of the longevity manlihwa extract according to an experimental example (**p <0.01, Scale bar = 100 μm). Histological changes of the nasal mucosa observed under a microscope after PAS (x200) staining. Arrows indicate PAS stained goblet cells, data represent mean±SEM.
Figure 9 is a result of evaluating the rhinitis inhibitory efficacy of the longevity manlihwa extract according to an experimental example (Scale bar = 100 μm). All slides were scored manually as IL-4 expression was found to be heterogeneous in the cytoplasm. Five random sections from five groups were taken and the staining intensity was scored. H-score was calculated as Σ i × pi. where i is the intensity score (0, unstained; 1, weak; 2, moderate; 3, strong), and pi represents the percentage of cells showing that intensity.
10 is an evaluation result of the rhinitis inhibitory efficacy of the extract of Jangsu Manlihwa according to an experimental example, as in FIG. 9 (Scale bar = 100 μm).

Hereinafter, the present disclosure will be described in detail.

In one aspect, the present disclosure provides an anti-allergic composition comprising Forsythia velutina Nakai extract as an active ingredient.

In another aspect, the present disclosure provides a composition for the prevention, improvement and/or treatment of allergies comprising Forsythia velutina Nakai extract as an active ingredient.

As used herein, the active ingredient refers to a component that exhibits the desired activity alone or exhibits activity together with a carrier that has no activity by itself.

In the present application, allergy is a general term for in vivo reaction changes caused by an antigen-antibody reaction in contact with a certain foreign substance (allergen). The type of the exogenous substance is not limited, and may specifically include pollen, drugs, vegetable fibers, fine dust, bacteria, food, dyes, or chemicals, but is not limited thereto.

As used herein, the term for prevention or treatment of allergy includes both prevention and treatment of allergy and allergy-related diseases. Methods of prevention or treatment are not limited, and for example, the disease can be prevented by fundamentally suppressing the production of allergens, etc., but is not limited thereto.

As used herein, the term "allergy improvement" includes all uses for reducing or alleviating the severity of allergies and allergy-related diseases. Specifically, it may include reducing or alleviating the degree of a disease that has already occurred, and considering that the composition of the present disclosure fundamentally suppresses allergens, it will be possible to prevent allergies and allergy-related diseases, but are limited thereto It is not.

In an exemplary embodiment, the allergy is allergic rhinitis, hay fever, Quincke's edema, anaphylaxis, hives, allergic conjunctivitis, and allergies. It may be one or more selected from the group consisting of allergic keratitis.

Herein, the extract of Manliflower Jangsu means to include all types of additional processing such as crude extract of Manliflower Jangsu as well as processed products of the extract, such as drying, concentration, fractionation, and fermentation.

In one exemplary embodiment, the longevity manlihwa extract may be prepared by including the following steps, but is not limited thereto.

1) extracting by adding an extraction solvent to the longevity flower;

2) filtering the extract of 'step 1)'; and

3) preparing an extract by concentrating the filtered extract of 'step 2)' under reduced pressure.

In an exemplary embodiment, the longevity manliflower extract may be prepared by further comprising the step of 4) preparing a fraction by additionally extracting the extract of 'step 3)' with an organic solvent.

The longevity manli flower of step 1) can be used without restrictions such as cultivated, collected, or commercially available.

In an exemplary embodiment, the extraction solvent in step 1) is water, alcohol or a mixture thereof, preferably a solvent selected from C ₁ to C ₆ , or C ₁ to C ₄ lower alcohols or mixed solvents thereof. It can be used, but is not limited thereto. In addition, the amount of the extraction solvent is preferably 1 to 20 times the weight of longevity, but may be used 10 times, but is not limited thereto.

In an exemplary embodiment, the extract may be extracted with one or more solvents selected from the group consisting of water and lower alcohols having 1 to 4 carbon atoms.

In an exemplary embodiment, the extract may be an aqueous ethanol extract.

In an exemplary embodiment, the aqueous ethanol solution may have a concentration of 70 to 95% (v/v).

In an exemplary embodiment, the extraction method of step 1) includes hot water extraction, immersion extraction, reflux cooling extraction, ultrasonic extraction, and the like, and may be extracted 1 to 5 times. The extraction temperature may be preferably 10 to 100 °C, or 30 to 70 °C, and extraction may be performed at room temperature, but is not limited thereto. The extraction time may be 1 hour to 7 days, but is not limited thereto.

In another exemplary embodiment, the extraction method is a method using an extraction device such as supercritical extraction, subcritical extraction, high-temperature extraction, or high-pressure extraction, or a method using an adsorption resin including XAD and HP-20, or using a microorganism Conventional extraction methods in the art, such as fermentation or natural fermentation, may be used.

According to an exemplary embodiment, it is possible to prepare the longevity manlihwa extract by a supercritical fluid extraction method by decompression by carbon dioxide and high temperature, and in general, the supercritical fluid is a liquid that has when a gas reaches a critical point under high temperature and high pressure conditions It has the properties of a gas and chemically has a polarity similar to that of non-polar solvents. Due to these characteristics, supercritical fluids are used for extraction of fat-soluble substances. Carbon dioxide becomes a supercritical fluid with both liquid and gaseous properties as the pressure and temperature go through the process of reaching the critical point due to the operation of the supercritical fluid device, and as a result, the solubility in fat-soluble solutes increases. When supercritical carbon dioxide passes through an extraction vessel containing a certain amount of sample, the fat-soluble substances contained in the sample are extracted by supercritical carbon dioxide. After extracting fat-soluble substances, if supercritical carbon dioxide containing a small amount of co-solvent is passed through the sample remaining in the extraction vessel again, components that were not extracted with pure supercritical carbon dioxide alone can be extracted, and these co-solvents include chloroform, ethanol, One or a mixture of two or more selected from the group consisting of methanol, water, ethyl acetate, hexane, and diethyl ether may be used. Most of the extracted samples contain carbon dioxide, which is volatilized into the air at room temperature, and the co-solvent can be removed with a vacuum evaporator.

According to an exemplary embodiment, it is possible to prepare an extract of Jangsu Manlihwa by an ultrasonic extraction method using energy generated by ultrasonic vibration. Ultrasound can destroy insoluble substances included in a sample in an aqueous solvent, and the high local temperature generated at this time increases the kinetic energy of reactant particles located around it, so sufficient energy for the reaction is obtained, and ultrasonic energy The impact effect of the induction of high pressure increases the mixing effect of the substance and the solvent contained in the sample to increase the extraction efficiency.

According to an exemplary embodiment, it is possible to prepare a longevity manlihwa extract through a fermentation process. After finely crushing Jangsu Manlihwa to about 100 to 500 mesh, a conventional microbial culture medium is added at 1 to 50 g/L, and microorganisms such as yeast or lactic acid bacteria are added in an amount of 10,000 to 100,000 cfu/L. The culture temperature is cultured under typical microbial culture conditions of 30 to 37 ° C., pH is 5 to 7, and cultured for about 5 to 10 days under aerobic or anaerobic conditions, and then the extract can be obtained through aging and filtration.

In one exemplary embodiment, the vacuum concentration in step 3) may use a vacuum rotary evaporator, but is not limited thereto. In addition, it may be dried after concentration under reduced pressure, and drying may include vacuum drying, vacuum drying, boiling drying, spray drying, room temperature drying, or freeze drying.

In an exemplary embodiment, the organic solvent in step 4) may be normal-hexane, methylene chloride, ethyl acetate or normal-butanol, but is not limited thereto.

In an exemplary embodiment, the fraction in step 4) is a normal-hexane fraction obtained by suspending the extract of Manliflower in water and sequentially fractionating normal-hexane, methylene chloride, ethyl acetate, normal-butanol, and water, It may be any one of a methylene chloride fraction, an ethyl acetate fraction, a normal-butanol fraction, or a water fraction, but is not limited thereto. The fraction may be obtained by repeating the fractionation process 1 to 5 times, preferably 3 times, from the Jangsu manlihwa extract, and it may be preferable to concentrate under reduced pressure after fractionation.

In one exemplary embodiment, the extract may be included in a concentration of 1 to 1,000 ppm (w / v). In another exemplary embodiment, the extract is 1 ppm or more, 5 ppm or more, 10 ppm or more, 15 ppm or more, 20 ppm or more, 25 ppm or more or 30 ppm or more, and 1,000 ppm or less, 900 ppm or less, 800 ppm 700 ppm or less, 600 ppm or less, 500 ppm or less, 400 ppm or less, 300 ppm or less, 200 ppm or less, 100 ppm or less, 90 ppm or less, 80 ppm or less, 70 ppm or less, 60 ppm or less, 50 ppm or less, It may be included in a concentration that is 40 ppm or less, 30 ppm or less, 20 ppm or less, or 10 ppm or less. For example, the extract may be included in a concentration of 6.25 to 50 ppm, 12.5 to 50 ppm, 16.6 to 50 ppm, 6.25 to 25 ppm, 12.5 to 25 ppm, or 16.6 to 25 ppm.

In an exemplary embodiment, the composition may inhibit phosphorylation of STAT6.

In an exemplary embodiment, the composition may inhibit degranulation of mast cells.

In an exemplary embodiment, the composition may be a pharmaceutical composition for preventing or treating allergic rhinitis.

In one exemplary embodiment, the dosage form of the pharmaceutical composition may be a solution, suspension, emulsion, gel, drop, cream, ointment, patch, pad or spray, but is not limited thereto. The formulation can be easily prepared according to a conventional method in the art, and includes excipients, wetting agents, emulsification accelerators, suspending agents, salts or buffers for osmotic pressure control, coloring agents, spices, stabilizers, preservatives, preservatives, or other commonly used additives. Supplements may be used in moderation.

In an exemplary embodiment, the pharmaceutical composition may be administered orally, parenterally, rectal, topical, transdermal, intravenous, intramuscular, intraperitoneal, subcutaneous, etc. according to the desired method, and the active ingredient of the pharmaceutical composition is It will vary depending on the age, sex, weight, pathological condition and severity of the subject to be administered, the route of administration, or the judgment of the prescriber. Determination of the application amount based on these factors is within the level of a person skilled in the art, and its daily administration dose is, for example, 0.001 mg/kg/day to 100 mg/kg/day, more specifically 0.5 mg/kg/day to 50 mg/kg/day. kg/day, but is not limited thereto.

In one exemplary embodiment, it may be a food composition for improving allergic rhinitis (allergic rhinitis).

In an exemplary embodiment, the food composition may be a health food or health functional food.

Food compositions in the present disclosure may provide various types of food additives or functional foods. Specifically, it can be processed into leached tea, liquid tea, beverages, fermented milk, cheese, yogurt, juice, probiotics or health supplements containing the composition, and can be used in the form of various other food additives.

In an exemplary embodiment, the food composition may further include other ingredients that can give a synergistic effect to the main effect within a range that does not impair the main effect of the active ingredient. For example, additives such as fragrances, pigments, bactericides, antioxidants, preservatives, humectants, thickeners, inorganic salts, emulsifiers, or synthetic polymers may be further included to improve physical properties. In addition, auxiliary ingredients such as water-soluble vitamins, oil-soluble vitamins, high-molecular peptides, high-molecular polysaccharides, or seaweed extract may be further included. Those skilled in the art can select and mix the above components without difficulty depending on the formulation or purpose of use, and the amount of addition can be selected within a range that does not impair the purpose and effect of the present disclosure. For example, the amount of the components added may range from 0.001 to 5% by weight, or from 0.01 to 3% by weight based on the total weight of the composition.

Hereinafter, the present disclosure will be described in more detail through examples. These examples are only for exemplifying the present disclosure, and it will be apparent to those skilled in the art that the scope of the present disclosure is not to be construed as being limited by these examples.

Example One. Longevity Manly Flower extract manufacturing

Jangsu Manlihwa extract was prepared from Forsythia velutina Nakai as follows and used in the following experiments. Jangsu Manliflower extract (E1) grown in the sun and Jangsu Manliflower extract (E2) grown in the shade were prepared from Jangsu Manliflower grown in the sun and Jangsu Manliflower grown in the shade. Specifically, 1 kg of each outpost was extracted with a cold needle using a 70% (v/v) aqueous ethanol solution, and extracted three times by extracting for 24 hours. After extraction, the mixture was filtered using a filter paper, and the filtered extract was concentrated to obtain a concentrate of 175.2 mg, which was used in the experiment.

comparative example 1. Preparation of forsythia extract

A forsythia extract was prepared from Forsythia koreana as follows and used in the following experiments. A Forsythia extract (W) using water as an extraction solvent and a Forsythia extract (E) using an aqueous ethanol solution were prepared from the outpost of Forsythia. Specifically, 10 L of water and 10 L of ethanol aqueous solution were added to 1 kg of Forsythia outpost, respectively, heated at 80 ° C. by a reflux extraction method, and the extract was passed through filter paper. The above process was repeated three times, and the solvent was evaporated under reduced pressure to obtain 134.5 mg of the concentrate, which was used in the experiment.

comparative example 2. annual school extract manufacturing

Forsythia viridissima Forsythia viridissima An extract of Yeongyo was prepared as follows from the fruit and used in the following experiments. Yonkyo extract (W) using water as an extraction solvent and Yonkyo extract (E) using an aqueous ethanol solution as an extraction solvent were prepared. Specifically, 10 L of water and 10 L of an aqueous ethanol solution were added to 1 kg of annualized bridge, respectively, heated at 80 ° C. by a reflux extraction method, and the extract was passed through filter paper. The above process was repeated three times, and the solvent was evaporated under reduced pressure to obtain 121.2 mg of the concentrate, which was used in the experiment.

Experimental example 1-1. Cytotoxicity assessment 1

The cytotoxicity of the Jangsu manlihwa extract prepared in Example 1 was confirmed as follows.

Raw 264.7 cells used in the MTT assay were injected with 100 μL of 40,000 cells per well into 96 wells and cultured for 24 hours, and then treated with extracts by concentration (3.125 to 100 μg/mL) and additionally incubated at 37 ° C for 24 hours. cultured. Thereafter, 10 μL of EZ-Cytox reagent was injected, followed by incubation in an incubator for 1 hour, and absorbance was measured using a UV-VIS plate reader.

As a result, it was confirmed that the extract of Jangsu Manlihwa exhibited cytotoxicity at a certain concentration or higher, and thus it was preferable to treat at a low concentration, for example, a concentration of 50 μg/mL or less or 25 μg/mL or less (see FIG. 1).

Experimental example 1-2. Cytotoxicity assessment 2

The cytotoxicity of the extracts prepared in Example 1 and Comparative Examples 1 and 2 was confirmed as follows.

For the HEK cells used in the MTT assay, 100 μL of 40,000 cells per well was injected into 96 wells and cultured for 24 hours, then the extract was processed by concentration (12.5 to 50 μg/mL) and cultured in an incubator at 37 ° C for additional 24 hours. did Thereafter, 10 μL of EZ-Cytox reagent was injected, followed by incubation in an incubator for 1 hour, and absorbance was measured using a UV-VIS plate reader.

As a result, it was confirmed that the ethanol extract of Yeongyo showed the highest cytotoxicity when treated at a concentration of 50 μg/mL among the extracts (see FIG. 2).

Experimental example 2. STAT6 Activity inhibition efficacy evaluation

STAT6 is activated by IL-4 in an allergic response and activates the lower signaling pathway to induce an allergic response. The STAT6 activity inhibitory effect of the Jangsu Manlihwa extract prepared in Example 1 and the Forsythia extract and Yeongyo extract prepared in Comparative Examples 1 and 2, respectively, was confirmed through SEAP (secreted embryonic alkaline phosphatase) expression as follows.

HEK-Blue cells were inoculated in a 96-well plate at a concentration of 40,000 cells/well and cultured for 24 hours at 37 °C and 5% CO ₂ conditions. Thereafter, each extract was treated at different concentrations (0.4 to 100 μg/mL), pretreated for 2 hours, and then treated with IL-4 (1 ng/mL) and cultured for 24 hours. After obtaining the culture supernatant and reacting with quanti-blue ^TM , the absorbance was measured at 620 nm. The STAT6 activity of the other experimental groups was compared with the STAT6 activity of the IL-4 alone treatment group not treated with the extract as 100%.

As a result, it was confirmed that the Jangsu manlihwa extract inhibited STAT6 activity in a concentration-dependent manner (see FIG. 3). In addition, it was confirmed that the Jangsu manlihwa extract had a remarkably superior effect of inhibiting STAT6 activity compared to the Forsythia extract or the Yeongyo extract (see FIG. 4).

Experimental example 3. degranulation Inhibitory efficacy evaluation

The mast cell degranulation inhibitory effect of the Jangsu Manlihwa extract prepared in Example 1 was confirmed as follows.

RBL-2H3 cells, a mast cell line, were inoculated in a 96-well plate at a concentration of 25,000 cells/well, and 100 ng/mL of IgE was added thereto, followed by incubation at 37 °C and 5% CO ₂ for 24 hours. Thereafter, the extract of Jangsu Manlihwa was treated at different concentrations (5.55-50 μg/mL), pre-treated for 2 hours, and then treated with DNP-BSA (100 ng/mL) and cultured for 2 hours. The culture supernatant was taken and reacted in the dark with substrate buffer for 1 hour at 37° C., and then the reaction was stopped by adding a stop solution, and absorbance was measured at 405 nm. Based on the degranulation inhibitory activity of the IgE and DNP-BSA treated groups not treated with the extract, the degranulation inhibitory activities of the other experimental groups were compared.

As a result, it was confirmed that the extract of Jangsu Manlihwa had a degranulation inhibitory effect in a concentration-dependent manner (see FIG. 5).

Experimental example 4. Evaluation of Rhinitis Inhibiting Efficacy in Rodent Rhinitis Model

Rhinitis inhibitory efficacy of the longevity manlihwa extract prepared in Example 1 was confirmed as follows in a rodent rhinitis model.

Rhinitis was induced by IP injection of physiological saline (300 μL), OVA (Ovalbumin, 50 μg), and alum (1 mg) to 12-week-old Balb/c male mice (n=5/group). From the 21st day after rhinitis was induced, physiological saline (30 μL) and OVA (500 μg) were injected into the nasal passages of mice over 7 days. In addition, rhinitis inhibitory efficacy was compared by administering Ciclesonide (CIC) to the experimental group as a positive control group and Jangsu Manlihwa extract. Before measurement, OVA was injected into the nasal cavity of the mouse and behavior of the mouse was observed for 10 minutes.

As a result, it was confirmed that the Jangsu Manlihwa extract had rhinitis inhibitory efficacy and significantly better rhinitis inhibitory efficacy than ciclesonide (see FIGS. 6 to 10).

Formulation examples of the composition according to one aspect of the present disclosure will be described below, but can also be applied to various other formulations, which are only intended to be specifically described, not intended to limit the present disclosure.

[Formulation Example 1] Soft capsule preparation

Soft capsules were prepared by mixing 150 mg of Manliflower ethanol extract of Example 1, 2 mg of palm oil, 8 mg of hydrogenated palm oil, 4 mg of yellow wax, and 6 mg of lecithin, and filling 400 mg per capsule according to a conventional method.

[Formulation Example 2] Tablets

150 mg of Jangsu Manlihwa ethanol extract of Example 1, 100 mg of glucose, 50 mg of red ginseng extract, 96 mg of starch, and 4 mg of magnesium stearate were mixed, 40 mg of 30% ethanol was added to form granules, and then dried at 60 ° C. and compressed into tablets using a tablet press.

[ formulation example 3] granules

After mixing 150 mg of Jangsu Manlihwa ethanol extract, 100 mg of glucose, 50 mg of red ginseng extract, and 600 mg of starch, and adding 100 mg of 30% ethanol to form granules, drying at 60 ° C. to form granules, Filled the pore. The final weight of the content was 1 g.

[ formulation example 4] Drinking agent

150 mg of Jangsu Manlihwa ethanol extract of Example 1, 10 g of glucose, 50 mg of red ginseng extract, 2 g of citric acid, and 187.8 g of purified water were mixed and filled into a bottle. The final volume of the content was 200 ml.

[Formulation Example 5] Manufacture of health food

Ethanol extract of Jangsu Manlihwa of Example 1 ............ 1000 mg

vitamin mixture

Vitamin A Acetate .................70 μg

Vitamin E ................................. 1.0 mg

Vitamin B1 ................................. 0.13 mg

Vitamin B2 ................................... 0.15 mg

Vitamin B6 ................................. 0.5 mg

Vitamin B12........................... 0.2 μg

Vitamin C ................................. 10 mg

Biotin ................................................ 10 μg

Nicotinamide ................................. 1.7 mg

Folic acid ................................. 50 μg

Calcium Pantothenate ................... 0.5 mg

mineral mixture

Ferrous Sulphate ................................. 1.75 mg

Zinc Oxide ................................. 0.82 mg

Magnesium Carbonate ........................... 25.3 mg

Potassium Phosphate Monobasic ................................. 15 mg

Dibasic Calcium Phosphate ................... 55 mg

Potassium Citrate ................................... 90 mg

Calcium Carbonate ................................. 100 mg

Magnesium Chloride ................... 24.8 mg

Although the composition ratio of the above vitamin and mineral mixture was mixed with ingredients suitable for relatively healthy food in a preferred embodiment, the mixing ratio may be arbitrarily modified, and the above ingredients are mixed according to the usual health food manufacturing method, and then Granules are prepared and can be used for preparing health food compositions according to conventional methods.

[ formulation example 6] Manufacture of health drinks

Ethanol extract of Jangsu Manlihwa of Example 1 ........... 1000 mg

Citric acid ................................. 1000 mg

Oligosaccharides ................................ 100 g

Plum concentrate ................................. 2 g

Taurine ................................................ 1 g

Add purified water to make the total ............ 900 ml

After mixing the above components according to the usual health drink manufacturing method, stirring and heating at 85 ° C. for about 1 hour, the resulting solution is filtered and obtained in a sterilized 2-liter container, sealed and sterilized, and then refrigerated. It was used for preparing a health drink composition according to the method.

Although the composition ratio is a mixture of ingredients suitable for a relatively favorite beverage in a preferred embodiment, the blending ratio may be arbitrarily modified according to regional and ethnic preferences such as the class of demand, the country of demand, and the purpose of use. Those skilled in the art to which the present disclosure pertains will be able to make various applications and modifications within the scope of the present disclosure based on the above information.

As above, specific parts of the present disclosure have been described in detail, and for those skilled in the art, it is clear that these specific descriptions are only preferred embodiments, and the scope of the present disclosure is not limited thereby. something to do. Accordingly, the substantial scope of the disclosure will be defined by the appended claims and their equivalents.

Claims (10)

A pharmaceutical composition for preventing or treating allergic rhinitis, comprising Forsythia velutina Nakai extract as an active ingredient.
According to claim 1,
The extract is extracted with one or more solvents selected from the group consisting of water and lower alcohols having 1 to 4 carbon atoms, a pharmaceutical composition for preventing or treating allergic rhinitis.
According to claim 2,
The extract is an aqueous ethanol extract, a pharmaceutical composition for the prevention or treatment of allergic rhinitis.
According to claim 1,
The extract is contained in a concentration of 1 to 1,000 ppm (w / v), a pharmaceutical composition for the prevention or treatment of allergic rhinitis.
According to claim 1,
The composition is to inhibit the phosphorylation of STAT6, a pharmaceutical composition for the prevention or treatment of allergic rhinitis.
A food composition for improving allergic rhinitis comprising Forsythia velutina Nakai extract as an active ingredient.
According to claim 6,
The extract is extracted with one or more solvents selected from the group consisting of water and lower alcohols having 1 to 4 carbon atoms, a food composition for improving allergic rhinitis.
According to claim 7,
The extract is an aqueous ethanol extract, a food composition for improving allergic rhinitis.
According to claim 6,
The extract is contained in a concentration of 1 to 1,000 ppm (w / v), a food composition for improving allergic rhinitis.
According to claim 6,
The composition is to inhibit phosphorylation of STAT6, a food composition for the improvement of allergic rhinitis.

Images